14.95

2.75% 0.40

After Hours: 14.95

Anika Therapeutics Inc (ANIK)

Overview News Price History Option Chain Financials Discussions Forecast

Anika Therapeutics Inc stock is traded at $14.95, with a volume of 96,293. It is up +2.75% in the last 24 hours and up +1.01% over the past month. Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.

Previous Close:

$14.55

Open:

$14.57

24h Volume:

96,293

Relative Volume:

0.66

Market Cap:

$198.92M

Revenue:

$116.26M

Net Income/Loss:

$-11.08M

P/E Ratio:

-18.88

EPS:

-0.7917

Net Cash Flow:

$1.04M

1W Performance:

-2.03%

1M Performance:

+1.01%

6M Performance:

+51.78%

1Y Performance:

+3.17%

1-Day Range:

$14.57

$15.18

1-Week Range:

$11.92

$15.69

52-Week Range:

$7.8701

$16.24

Anika Therapeutics Inc Stock (ANIK) Company Profile

Name

Anika Therapeutics Inc

Sector

Healthcare (1106)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

(781) 457-9000

Address

32 WIGGINS AVENUE, BEDFORD, MA

Employee

235

Twitter

Next Earnings Date

2026-04-29

Latest SEC Filings

ANIK's Discussions on Twitter

Compare ANIK vs TAK, ZTS, TEVA, HLN, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANIK Anika Therapeutics Inc	14.95	193.60M	116.26M	-11.08M	1.04M	-0.7917
TAK Takeda Pharmaceutical Co Adr	16.55	52.32B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	112.54	47.38B	9.47B	2.67B	2.28B	6.0218
TEVA Teva Pharmaceutical Industries Ltd Adr	35.86	41.16B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.17	41.02B	14.54B	2.22B	2.58B	0.4871
UTHR United Therapeutics Corp	572.20	24.67B	3.18B	1.33B	1.04B	27.90

Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-17-25	Initiated	B. Riley Securities	Buy
Nov-01-24	Reiterated	Barrington Research	Outperform
Aug-14-23	Upgrade	Barrington Research	Mkt Perform → Outperform
Mar-07-23	Downgrade	Barrington Research	Outperform → Mkt Perform
Nov-09-22	Upgrade	Barrington Research	Mkt Perform → Outperform
Oct-14-22	Resumed	Stephens	Equal-Weight
Mar-09-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Mar-09-22	Downgrade	Stephens	Overweight → Equal-Weight
Nov-16-21	Initiated	Stephens	Overweight
Jul-16-21	Initiated	UBS	Neutral
Dec-16-20	Upgrade	Barrington Research	Mkt Perform → Outperform
May-08-20	Downgrade	Barrington Research	Outperform → Mkt Perform
Jan-21-20	Upgrade	Sidoti	Neutral → Buy
Jan-10-20	Upgrade	First Analysis Sec	Outperform → Strong Buy
Nov-05-19	Initiated	BWS Financial	Sell
Sep-24-19	Reiterated	Barrington Research	Outperform
Sep-23-19	Downgrade	First Analysis Sec	Strong Buy → Outperform
Jul-25-19	Upgrade	First Analysis Sec	Neutral → Strong Buy
Feb-22-19	Downgrade	First Analysis Sec	Outperform → Neutral
Feb-22-19	Downgrade	Sidoti	Buy → Neutral
Jul-27-18	Upgrade	Barrington Research	Mkt Perform → Outperform
Jun-20-18	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-20-18	Downgrade	First Analysis Sec	Overweight → Equal-Weight
May-04-18	Upgrade	Barrington Research	Mkt Perform → Outperform
Feb-23-18	Downgrade	Barrington Research	Outperform → Mkt Perform
Jan-24-18	Upgrade	First Analysis Sec	Equal-Weight → Overweight
Oct-27-17	Reiterated	Barrington Research	Outperform
May-09-16	Upgrade	Singular Research	BUY - Long-Term → Buy
Apr-27-16	Downgrade	Northland Capital	Outperform → Market Perform
Feb-26-16	Reiterated	Barrington Research	Outperform

View All

Anika Therapeutics Inc Stock (ANIK) Latest News

04:51 AM

Insider Buying: HENNEMAN JOHN B III Acquires 5,000 Shares of Ani - GuruFocus

04:51 AM

06:32 AM

Anika maintains 2026 revenue guidance of $114M-$122.5M while highlighting Integrity growth and Hyalofast FDA response work - MSN

06:32 AM

12:31 PM

Anika Therapeutics Q1 2026 earnings preview - MSN

12:31 PM

May 04, 2026

Anika Therapeutics director John Henneman buys $73,319 in shares By Investing.com - Investing.com Canada

May 04, 2026

Anika Therapeutics director John Henneman buys $73,319 in shares - Investing.com

May 04, 2026

Anika Therapeutics (ANIK) director adds 5,000 shares in open-market buy - Stock Titan

May 04, 2026

May 03, 2026

President of Anika Therapeutics Picks Up 51% More Stock - Yahoo Finance

May 03, 2026

May 02, 2026

Anika Therapeutics (NASDAQ:ANIK) Rating Lowered to "Buy" at Wall Street Zen - MarketBeat

May 02, 2026

May 01, 2026

ANIK | Anika Therapeutics Inc Insider Trading - Quiver Quantitative

May 01, 2026

Anika Therapeutics Projects $114 Million Revenue Growth for Fiscal 2026 - HarianBasis.co

May 01, 2026

Apr 30, 2026

Insider Buying: Stephen Griffin Acquires Shares of Anika Therape - GuruFocus

Apr 30, 2026

Anika Therapeutics (NASDAQ:ANIK) CEO Purchases $149,938.00 in Stock - MarketBeat

Apr 30, 2026

Anika Therapeutics Q1 2026 Financial Results: Revenue, Losses, and Key Financial Statements Overview - Minichart

Apr 30, 2026

Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock By Investing.com - Investing.com India

Apr 30, 2026

Anika Therapeutics’ CEO Stephen Griffin buys $149,880 in company stock - Investing.com

Apr 30, 2026

Insider Purchase: President and CEO of $ANIK Buys 12,200 Shares - Quiver Quantitative

Apr 30, 2026

Anika Therapeutics (ANIK) CEO buys 12,200 shares in open market - Stock Titan

Apr 30, 2026

Anika Therapeutics : 2026 Proxy Statement - marketscreener.com

Apr 30, 2026

Bullish On Anika Therapeutics’s Pullback As Integrity Scales (NASDAQ:ANIK) - Seeking Alpha

Apr 30, 2026

Rotator cuff procedure advances driven by biology, Anika Therapeutics claims - Traders Union

Apr 30, 2026

(ANIK) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Apr 30, 2026

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q1 2026 Earnings Call Transcript - Insider Monkey

Apr 30, 2026

Revenue climbs 13% as Anika Therapeutics (NASDAQ: ANIK) boosts margins but stays in loss - Stock Titan

Apr 30, 2026